Clinical Trial News and Research

RSS

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA.

18 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company's SynCon™ Chikungunya virus DNA vaccine induced protective neutralizing antibody responses in a preclinical non-human primate model.

18 Nov 2009

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Transcendental Meditation may be effective in reducing BP and psychological distress

"The Transcendental Meditation Program, a widely-used standardized program to reduce stress, showed significant decreases in blood pressure and improved mental health in young adults at risk for hypertension," said David Haaga, PhD, co-author of the study and professor of psychology at American University in Washington, D.C.

18 Nov 2009

Drug market for acute ischemic stroke to reach $450M in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in 2008 to $450 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

18 Nov 2009

Review of the results of Phase 2b clinical trial on PASCAL announced

ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

18 Nov 2009

Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Mount Sinai School of Medicine is one of 12 sites nationwide participating in the first Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease. The study is the first multicenter neurosurgical intervention in Alzheimer's research in the U.S.

18 Nov 2009

Phase III randomized clinical trial for Alpharadin to be commenced

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.

18 Nov 2009

First-quarter fiscal 2010 results announced by Senesco Technologies

Senesco Technologies, Inc. today reported financial results for the three months ended September 30, 2009.

17 Nov 2009

Neuralstem provides financial and business updates for third-quarter 2009

Neuralstem, Inc. today provided a financial and business update for the third quarter ended September 30, 2009.

17 Nov 2009

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.

17 Nov 2009

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

A new, reversible antiplatelet drug did not demonstrate superiority over a current irreversible one in reducing the composite of death, heart attack or ischemia-related revascularization in the 48 hours after angioplasty, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

17 Nov 2009

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.

17 Nov 2009

FDA's BPAC renders positive opinion on Phase III clinical trial of INTERCEPT Blood System

Cerus Corporation announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets.

17 Nov 2009

ARCA biopharma provides financial and Gencaro NDA update

ARCA biopharma, Inc. today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for ARCA’s New Drug Application (NDA) seeking approval for GencaroTM (bucindolol hydrochloride) for the treatment of patients with chronic heart failure. Following receipt of the CRL, the Company and the FDA have held a series of meetings to discuss how best to address the requirements identified in the CRL.

17 Nov 2009

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

17 Nov 2009

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Targeted Genetics Corporation today announced its financial results for the third quarter ended September 30, 2009.

17 Nov 2009

Scientists develop new technique to measure brain volume loss for monitoring of Alzheimer's disease

In a study that promises to improve diagnosis and monitoring of Alzheimer's disease, scientists at the University of California, San Diego have developed a fast and accurate method for quantifying subtle, sub-regional brain volume loss using magnetic resonance imaging (MRI). The study will be published the week of November 16 in the Proceedings of the National Academy of Sciences (PNAS).

16 Nov 2009

Clinical Trial News and Research

Recent data from CNSBio's Phase IIa CNSB015 trial to be presented at the Neuropathic Pain conference

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

SynCon Chikungunya virus DNA vaccine induces protective neutralizing antibody responses in animal model

Pluristem’s PLX-PAD holds promise for critical limb ischemia

NeoPharm presents LE-DT Phase I data at the AACR conference

Transcendental Meditation may be effective in reducing BP and psychological distress

Drug market for acute ischemic stroke to reach $450M in 2018

Review of the results of Phase 2b clinical trial on PASCAL announced

Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Phase III randomized clinical trial for Alpharadin to be commenced

First-quarter fiscal 2010 results announced by Senesco Technologies

Neuralstem provides financial and business updates for third-quarter 2009

Advanced BioMedical Technologies commences animal tests with novel patented PA bio-absorbable material

New, reversible antiplatelet drug not superior than irreversible one in patients undergoing PCI

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

FDA's BPAC renders positive opinion on Phase III clinical trial of INTERCEPT Blood System

ARCA biopharma provides financial and Gencaro NDA update

Mount Sinai School of Medicine to participate in Phase 2 clinical trial to test gene therapy treatment for Alzheimer's disease

Targeted Genetics announces third quarter 2009 results; reports net income of $0.03 per common share

Scientists develop new technique to measure brain volume loss for monitoring of Alzheimer's disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News